Psoriasis and GLP-1

Psoriasis, often worsened by obesity, is challenging to manage, as excess weight can increase inflammation and reduce treatment effectiveness. However, a new generation of medications called GLP-1 agonists—such as semaglutide (Ozempic) and tirzepatide (Mounjaro)—is offering promise. These drugs not only aid weight loss but may also improve psoriasis symptoms, especially in patients with type 2 diabetes and obesity.

Moreover, combining GLP-1 agonists with biologics (e.g., adalimumab, infliximab) could enhance treatment by addressing both skin symptoms and underlying metabolic issues. Though research is still in early stages, this combination therapy holds potential to change the way psoriasis, particularly in overweight or diabetic patients, is managed.

Read more to explore the latest breakthroughs in psoriasis treatment and what the future holds.